Price Action Don’t Lie: Is Selling Dipexium Pharmaceuticals Inc Here a Winning Strategy?

Price Action Don't Lie: Is Selling Dipexium Pharmaceuticals Inc Here a Winning Strategy?

The stock of Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) is a huge mover today! The stock decreased 4.76% or $0.69 during the last trading session, hitting $13.81. About 54,127 shares traded hands. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) has risen 93.33% since February 29, 2016 and is uptrending. It has outperformed by 81.12% the S&P500.
The move comes after 7 months negative chart setup for the $142.91M company. It was reported on Oct, 4 by Barchart.com. We have $12.29 PT which if reached, will make NASDAQ:DPRX worth $15.72M less.

Analysts await Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) to report earnings on November, 11. They expect $-0.55 EPS, down 12.24% or $0.06 from last year’s $-0.49 per share. After $-0.52 actual EPS reported by Dipexium Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.77% negative EPS growth.

According to Zacks Investment Research, “Dipexium Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops and commercializes Locilex (TM), small peptide topical antibiotic for the treatment of certain mild and moderate skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds, and nasal colonization of methicillin-resistant staphylococcus aureus. Dipexium Pharmaceuticals, LLC is based in White Plains, New York.”

Insitutional Activity: The institutional sentiment decreased to 1 in Q2 2016. Its down 0.07, from 1.07 in 2016Q1. The ratio fall, as 5 funds sold all Dipexium Pharmaceuticals Inc shares owned while 10 reduced positions. 4 funds bought stakes while 11 increased positions. They now own 2.31 million shares or 15.44% less from 2.73 million shares in 2016Q1.
Goldman Sachs Group owns 78,255 shares or 0% of their US portfolio. Falcon Point Cap Ltd Limited Liability Company has invested 0.07% of its portfolio in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX). Broadfin Capital Llc holds 44,774 shares or 0.04% of its portfolio. Kingdon Capital Mgmt Limited Com holds 0.53% or 970,124 shares in its portfolio. Raymond James Assocs has 31,433 shares for 0% of their US portfolio. Tourbillon Limited Partnership accumulated 0.05% or 237,874 shares. Lombard Odier Asset Mgmt (Usa) last reported 152,065 shares in the company. 1492 Mgmt Lc reported 30,663 shares or 0.27% of all its holdings. Timpani Management Limited Liability has 0.27% invested in the company for 64,124 shares. The New York-based Tower Ltd Limited Liability Company (Trc) has invested 0% in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX). Deutsche Financial Bank Ag has 1,552 shares for 0% of their US portfolio. Moreover, Guggenheim Cap Ltd Limited Liability Company has 0% invested in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) for 37,939 shares. 683 Management Ltd Limited Liability Company accumulated 179,000 shares or 0.28% of the stock. Bridgeway Cap Mgmt Inc last reported 24,600 shares in the company. Natl Bank Of America De owns 60 shares or 0% of their US portfolio.

More notable recent Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on March 16, 2014, also Zacks.com with their article: “Dipexium Pharmaceuticals (DPRX) Worth a Look: Stock Up 8.8%” published on September 28, 2016, Quotes.Wsj.com published: “News Dipexium Pharmaceuticals Inc.DPRX” on March 09, 2014. More interesting news about Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) were released by: Prnewswire.com and their article: “Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent by European Union” published on September 07, 2016 as well as Zacks.com‘s news article titled: “Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%” with publication date: August 30, 2016.

DPRX Company Profile

Dipexium Pharmaceuticals, Inc., incorporated on January 14, 2010, is a late-stage pharmaceutical company. The Firm is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). As a topical antibiotic, Locilex affects only the area to which it is applied, and does not spread to the entire body through the bloodstream, which is host to a number of different bacteria other than bacteria causing the skin infection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment